# A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION

> **NCT04262375** · PHASE2 · WITHDRAWN · sponsor: **University Health Network, Toronto**

## Conditions studied

- Non Small Cell Lung Cancer
- Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Durvalumab
- **BIOLOGICAL:** Oleclumab

## Key facts

- **NCT ID:** NCT04262375
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-01
- **Primary completion:** 2024-01
- **Final completion:** 2024-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Overall clinical activity (ORR) for oleclumab + durvalumab is minimal across tumor types and does not support further evaluation of this doublet.
- **Last updated:** 2020-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04262375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04262375, "A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04262375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*